Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported EBT Margin of 76.25% for Q1 2026, up 8420.0% on a YoY basis from 0.89% in Q1 2025, and down 19.14% quarter-over-quarter from 64.0% in Q4 2025.
Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported EBT Margin for 15 years, with the latest figure at 76.25% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 8420.0% year-over-year to 76.25%; the trailing twelve-month figure through Mar 2026 stood at 89.42% (up 6399.0% YoY), and the FY2025 full-year result was 127.9%, up 4625.0% from the prior year.
- EBT Margin for Q1 2026 stood at 76.25%, down from 64.0% in the prior quarter.
- The five-year high for EBT Margin was 64.0% in Q4 2025, with the low at 211.37% in Q1 2023.
- Historically, EBT Margin has averaged 147.55% across 5 years, with a median of 155.91% in 2023.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 6597 bps — and 2026, when it jumped 8420 bps.
- Enanta Pharmaceuticals' EBT Margin stood at 123.04% in 2022, then plunged by 54 bps to 189.02% in 2023, then advanced by 29 bps to 133.89% in 2024, then surged by 52 bps to 64.0% in 2025, then decreased by 19 bps to 76.25% in 2026.
- The last three EBT Margin figures came in at 76.25% (Q1 2026), 64.0% (Q4 2025), and 123.42% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -76.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.25% |
| Dec 31, 2025 | -64.00% |
| Sep 30, 2025 | -123.42% |
| Jun 30, 2025 | -99.52% |
| Mar 31, 2025 | -160.45% |
| Dec 31, 2024 | -133.89% |
| Sep 30, 2024 | -199.81% |
| Jun 30, 2024 | -128.28% |
| Mar 31, 2024 | -184.82% |
| Dec 31, 2023 | -189.02% |
| Sep 30, 2023 | -155.91% |
| Jun 30, 2023 | -184.44% |
| Mar 31, 2023 | -211.37% |
| Dec 31, 2022 | -123.04% |
| Sep 30, 2022 | -129.62% |
| Jun 30, 2022 | -165.03% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -109.05% |
| Sep 30, 2021 | -141.65% |
| Jun 30, 2021 | -154.50% |